Results 81 to 90 of about 16,284 (266)

Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review. [PDF]

Cureus, 2023
Nahar S, Kanda S, Chatha U, Odoma VA, Pitliya A, AlEdani EM, Bhangu JK, Javed K, Manshahia PK, Yu AK.   +9 more
europepmc   +1 more source

Endothelin receptor antagonists: Potential in Alzheimer's disease

Pharmacological Research, 2011
Alzheimer's disease (AD) is believed to be initiated by the accumulation of neurotoxic forms of Aβ peptide within the brain. AD patients show reduction of cerebral blood flow (CBF), the extent of the reduction correlating with the impairment of cognition.
Palmer, JC, Love, S
openaire   +4 more sources

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

British Journal of Clinical Pharmacology, EarlyView.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post, Cayla Denney, Adam Cohen, Jens Jordan, Ulrich Limper   +4 more
wiley   +1 more source

Therapy for digital ulcers in patients with systemic scleroderma

Научно-практическая ревматология, 2019
As of now, there are several pharmacological directions in the treatment and prevention of Raynaud’s syndrome and digital ulcers, including various vasoactive drugs (calcium channel blockers, intravenous prostanoids, endothelin receptor antagonists ...
M. N. Starovoitova, O. V. Desinova
doaj   +1 more source

Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver [PDF]

, 1997
Yoshihiro Kitayama, Naoki Yamanaka, Eisuke Kawamura, N Kuroda, Eizo Okamoto   +4 more
openalex   +1 more source

Asymmetric Synthesis of a Selective Endothelin A Receptor Antagonist.

Chemical and Pharmaceutical Bulletin, 2002
AbstractFor Abstract see ChemInform Abstract in Full Text.
Koji Tomimoto, Yoshiaki Kato, Kenji Niiyama, Hideki Jona, Atsushi Akao, Shigemitsu Okada, Yoshimi Tsuchiya, Shouichi Hiraga, Toshiaki Mase   +8 more
openaire   +5 more sources

Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study. [PDF]

Pulm Ther, 2023
Omura J, Makanji Y, Tanabe N, Yu DY, Tan JY, Lim S, Kouhkamari MH, Casorso J, Wu DB, Bloomfield P.   +9 more
europepmc   +1 more source

Inhibitory effects of TAK‐044 on endothelin induced vasoconstriction in various canine arteries and porcine coronary arteries: a comparison with selective ET_A and ET_B receptor antagonists [PDF]

, 1997
Yumiko Awane‐Igata, Shota Ikeda, Toshifumi Watanabe   +2 more
openalex   +1 more source

Shared determinants of receptor binding for subtype selective, and dual endothelin‐angiotensin antagonists on the AT₁ angiotensin II receptor [PDF]

, 1998
David Dascal, Vaneet Nirula, Kimberly Lawus, Sung‐Eun Yoo, Thomas F. Walsh, Kathryn Sandberg   +5 more
openalex   +1 more source

The dark sides of the GPCR tree ‐ research progress on understudied GPCRs

British Journal of Pharmacology, EarlyView.
Abstract A large portion of the human GPCRome is still in the dark and understudied, consisting even of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion GPCRs, Frizzleds and taste receptors. However, it is undeniable that these GPCRs bring an untapped therapeutic potential that should be explored further.
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte   +10 more
wiley   +1 more source